Judith A Reinsdorf - Net Worth and Insider Trading
Judith A Reinsdorf Net Worth
The estimated net worth of Judith A Reinsdorf is at least $9 Million dollars as of 2023-10-01. Judith A Reinsdorf is the EVP and General Counsel of Tyco International PLC and owns about 190,237 shares of Tyco International PLC (TYC) stock worth over $9 Million. Details can be seen in Judith A Reinsdorf's Latest Holdings Summary section.
Transaction Summary of Judith A Reinsdorf
Judith A Reinsdorf Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Judith A Reinsdorf owns 5 companies in total, including Alexion Pharmaceuticals Inc (ALXN) , Johnson Controls International PLC (JCI) , and Cornerstone Building Brands Inc (CNR) among others .
Insider Ownership Summary of Judith A Reinsdorf
|Ticker||Comapny||Transaction Date||Type of Owner|
|ALXN||Alexion Pharmaceuticals Inc||2020-05-14||director|
|JCI||Johnson Controls International PLC||2007-06-29||EVP and General Counsel|
|CNR||Cornerstone Building Brands Inc||2022-07-25||director|
|NPO||EnPro Industries Inc||2021-09-01||director|
|NRIX||Nurix Therapeutics Inc||2021-10-01||director|
Judith A Reinsdorf Latest Holdings Summary
Judith A Reinsdorf currently owns a total of 1 stock. Judith A Reinsdorf owns 190,237 shares of Tyco International PLC (TYC) as of August 12, 2015, with a value of $9 Million.
Judith A Reinsdorf Form 4 Trading Tracker
According to the SEC Form 4 filings, Judith A Reinsdorf has made a total of 0 transactions in Tyco International PLC (TYC) over the past 5 years. The most-recent trade in Tyco International PLC is the sale of 111,026 shares on August 12, 2015, which brought Judith A Reinsdorf around $4 Million.
Insider Trading History of Judith A Reinsdorf
Judith A Reinsdorf Trading Performance
Judith A Reinsdorf Ownership Network
Ownership Network List of Judith A Reinsdorf
Ownership Network Relation of Judith A Reinsdorf
Judith A Reinsdorf Owned Company Details
What does Alexion Pharmaceuticals Inc do?
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.
Who are the key executives at Alexion Pharmaceuticals Inc?
Judith A Reinsdorf is the director of Alexion Pharmaceuticals Inc. Other key executives at Alexion Pharmaceuticals Inc include EVP & Chief Commercial Officer Brian Goff , EVP & Research & Development John J Orloff , and EVP & Chief Compliance Officer Indrani Lall Franchini .
Alexion Pharmaceuticals Inc (ALXN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Alexion Pharmaceuticals Inc (ALXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alexion Pharmaceuticals Inc (ALXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Alexion Pharmaceuticals Inc (ALXN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Alexion Pharmaceuticals Inc Insider Transactions
Judith A Reinsdorf Mailing Address
Above is the net worth, insider trading, and ownership report for Judith A Reinsdorf. You might contact Judith A Reinsdorf via mailing address: C. R. Bard, Inc., 730 Central Avenue, Murray Hill Nj 07974.